Condition: Multiple Myeloma · Multiple Myeloma in Relapse · Multiple Myeloma Progression · Sponsor: Essen Biotech
This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting BCMA or GPRC5D or both sequentially in the treatment of Relapsed/ Refractory Multiple myeloma
This description comes directly from the study's public registry record.
Rhoda M Smith, Phd · +12077706670 · clinical-trials@essen-biotech.com
Always discuss trial participation with your own doctor first.
| District One Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07032129